Halozyme Therapeutics, Inc. (HALO)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 47.04 |
| Open | 47.19 |
| Bid | 43.55 x 1200 |
| Ask | 45.78 x 900 |
| Day's range | 45.60 - 47.32 |
| 52-week range | 31.36 - 48.58 |
| Volume | |
| Avg. volume | 1,071,696 |
| Market cap | 6.315B |
| Beta (5Y monthly) | 1.23 |
| PE ratio (TTM) | 15.27 |
| EPS (TTM) | 3.00 |
| Earnings date | 08 Aug 2022 - 12 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 49.71 |
- Zacks
Halozyme's (HALO) ENHANZE Drives Stock: Rally to Continue?
Halozyme's (HALO) revenues are driven by strong demand for new partnered drugs developed using ENHANZE. Robust revenue growth is expected to continue in 2022.
- Zacks
Halozyme Therapeutics (HALO) Up 19.8% Since Last Earnings Report: Can It Continue?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- PR Newswire
Halozyme to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to present and host investor meetings at the Goldman Sachs 43rd Annual Global Healthcare Conference being held in Rancho Palos Verdes, CA on June 14-16, 2022.
© 2022 Yahoo. All rights reserved.
